Fausto Roila
Research Subjects
Fausto Roila has a total of 159 co-authors. Here are the top co-authors by number of shared publications:
Enzo Ballatori
Spinetoli, Ascoli Piceno, Italy
7 shared publicationsDavid Warr
Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, Canada
6 shared publications- Enzo Ballatori
Statistico Medico, Spinetoli (AP) - Italy
6 shared publications Sonia Fatigoni
Azienda Ospedaliera S. Maria S.C. Oncologia, Terni, Italy
5 shared publicationsBenedetta Ruggeri
Clinical Governance, ASUR Marche, AV5, Ascoli Piceno, Italy
4 shared publicationsJorn Herrstedt
Department of Oncology, Odense University, 5000, Odense, Denmark
4 shared publications
Latest Publications
- 6 August 2018
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 27 (3) , 1041-1047
Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO)
Fatigue is one of the most distressing symptoms of cancer patients. Its characteristics and impact on quality of life have not been fully explored and treatment of cancer-related fatigue in Italian oncological centers has not been codified.
- 6 August 2018
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 27 (3) , 1041-1047
Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO)
Fatigue is one of the most distressing symptoms of cancer patients. Its characteristics and impact on quality of life have not been fully explored and treatment of cancer-related fatigue in Italian oncological centers has not been codified.
- 28 June 2018
- Published by Springer Nature
- p. 461-480
State of the Art of Antiemetic Therapy
- Open Access
- 18 September 2017
- Published by Elsevier in Annals of Oncology
- Vol. 28 (suppl_5) , v548
Efficacy of neurokinin-1 receptor antagonists in the prevention of Chemotherapy-Induced Nausea and Vomiting in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis
Background: According to current ESMO – MASCC guidelines, a combination of a neurokinin-1 receptor antagonist (NK1RA), dexamethasone and a 5-HT3 receptor antagonist (5-HT3RA) is recommended to prevent carboplatin-induced emesis, with moderate level of confidence and not unanimous consensus. Our aim was to perform a meta-analysis of all randomized trials (RCTs) evaluating the role of a NK1RA in the prevention of emesis for patients receiving carboplatin.
- 18 September 2017
- Published by Elsevier in Annals of Oncology
- Vol. 28 (suppl_5) , v548
Open AccessEfficacy of neurokinin-1 receptor antagonists in the prevention of Chemotherapy-Induced Nausea and Vomiting in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis
Background: According to current ESMO – MASCC guidelines, a combination of a neurokinin-1 receptor antagonist (NK1RA), dexamethasone and a 5-HT3 receptor antagonist (5-HT3RA) is recommended to prevent carboplatin-induced emesis, with moderate level of confidence and not unanimous consensus. Our aim was to perform a meta-analysis of all randomized trials (RCTs) evaluating the role of a NK1RA in the prevention of emesis for patients receiving carboplatin.
- 14 September 2016
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 25 (1) , 295-296
Erratum to: 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy
- 14 September 2016
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 25 (1) , 295-296
Erratum to: 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy
- 11 August 2016
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 25 (1) , 289-294
2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy
Purpose An update of the recommendations for the prophylaxis of acute and delayed emesis induced by moderately emetogenic chemotherapy published after the last MASCC/ESMO antiemetic consensus conference in 2009 has been carried out. Methods A systematic literature search using PubMed from January 1, 2009 to January 6, 2015 with a restriction to papers in English was conducted. Results Overall, two randomized phase II and seven randomized phase III studies plus the results of three subgroup analysis of large phase III trials and those of a pilot study have been included. Conclusions In carboplatin-treated patients, a moderate benefit from adding an NK1 receptor antagonist to dexamethasone and a 5-HT3 receptor antagonist has been shown. However, in oxaliplatin-treated patients, contrasting results about the role of NK1 receptor antagonists have been obtained. At present, it is not possible to suggest a specific 5-HT3 receptor antagonist to use for the prevention of acute emesis in these patients. No routine prophylaxis for delayed emesis is recommended but in patients receiving moderately emetogenic chemotherapy with known potential for delayed emesis (e.g., oxaliplatin, doxorubicin, cyclophosphamide) the use of dexamethasone for days 2–3 can be considered.
- 11 August 2016
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 25 (1) , 289-294
2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy
Purpose An update of the recommendations for the prophylaxis of acute and delayed emesis induced by moderately emetogenic chemotherapy published after the last MASCC/ESMO antiemetic consensus conference in 2009 has been carried out. Methods A systematic literature search using PubMed from January 1, 2009 to January 6, 2015 with a restriction to papers in English was conducted. Results Overall, two randomized phase II and seven randomized phase III studies plus the results of three subgroup analysis of large phase III trials and those of a pilot study have been included. Conclusions In carboplatin-treated patients, a moderate benefit from adding an NK1 receptor antagonist to dexamethasone and a 5-HT3 receptor antagonist has been shown. However, in oxaliplatin-treated patients, contrasting results about the role of NK1 receptor antagonists have been obtained. At present, it is not possible to suggest a specific 5-HT3 receptor antagonist to use for the prevention of acute emesis in these patients. No routine prophylaxis for delayed emesis is recommended but in patients receiving moderately emetogenic chemotherapy with known potential for delayed emesis (e.g., oxaliplatin, doxorubicin, cyclophosphamide) the use of dexamethasone for days 2–3 can be considered.
- 10 May 2016
- Published by Taylor & Francis in Breast Cancer Management
- Vol. 5 (2) , 79-87
Management of Fatigue Following Breast Cancer Treatment
Cancer-related fatigue (CRF) is a very distressing symptom experienced by most cancer patients. CRF is a complex symptom and there is no agreement regarding the exact definition, the best measurement instrument or even the optimal treatment. CRF is an important problem especially in breast cancer patients, during and after treatment, in long-term survivors. In the last few decades survival rates have dramatically improved. Thus, the number of breast cancer survivors has increased and preservation of quality of life has become very important. This paper is a literature review of the studies published in the last 5 years on management of CRF and breast cancer patients. We distinguished CRF during and after oncological therapy and examined both pharmacological and nonpharmacological interventions.
- 10 May 2016
- Published by Taylor & Francis in Breast Cancer Management
- Vol. 5 (2) , 79-87
Management of Fatigue Following Breast Cancer Treatment
Cancer-related fatigue (CRF) is a very distressing symptom experienced by most cancer patients. CRF is a complex symptom and there is no agreement regarding the exact definition, the best measurement instrument or even the optimal treatment. CRF is an important problem especially in breast cancer patients, during and after treatment, in long-term survivors. In the last few decades survival rates have dramatically improved. Thus, the number of breast cancer survivors has increased and preservation of quality of life has become very important. This paper is a literature review of the studies published in the last 5 years on management of CRF and breast cancer patients. We distinguished CRF during and after oncological therapy and examined both pharmacological and nonpharmacological interventions.
- 1 August 2015
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 95 (2) , 214-221
A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients
- 1 August 2015
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 95 (2) , 214-221
A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients
- Open Access
- 1 May 2015
- Published by Aboutscience Srl in Global and Regional Health Technology Assessment
- Vol. 2 (2)
A new payment-by-results method for determining the fair price of new oncological drugs
The high prices of new cancer drugs are likely to undermine national health services sustainability. As a solution to this problem, the “payment-by-results” method was proposed and nowadays this approach is commonly implemented by national drug agencies: the drug manufacturer is set to refund to the National Health Service the price of the drug if the benefits expected for the patient are not achieved. Based on the payment-by-results approach, we developed a new and easy to implement model, that can set a fair price, so that neither industry, nor National Health Service can obtain an undue gain. Obviously, this price can be modified adjusting refund amounts to new healthcare and market conditions.
- 1 May 2015
- Published by Aboutscience Srl in Global and Regional Health Technology Assessment
- Vol. 2 (2)
Open AccessA new payment-by-results method for determining the fair price of new oncological drugs
The high prices of new cancer drugs are likely to undermine national health services sustainability. As a solution to this problem, the “payment-by-results” method was proposed and nowadays this approach is commonly implemented by national drug agencies: the drug manufacturer is set to refund to the National Health Service the price of the drug if the benefits expected for the patient are not achieved. Based on the payment-by-results approach, we developed a new and easy to implement model, that can set a fair price, so that neither industry, nor National Health Service can obtain an undue gain. Obviously, this price can be modified adjusting refund amounts to new healthcare and market conditions.
- Open Access
- 5 March 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26 (6) , 1248-1253
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study
A combination of aprepitant, a 5-HT3 receptor antagonist (r.a.), and dexamethasone is recommended for the prophylaxis of cisplatin-induced nausea and vomiting in the acute phase, and aprepitant + dexamethasone (A + D) in the delayed phase. The aim of this study was to verify if A + D is superior to metoclopramide plus dexamethasone (M + D) in preventing delayed emesis in cancer patients receiving the same prophylaxis for acute emesis. A randomized double-blind study comparing A + D versus M + D was completed in previously untreated cancer patients. Before chemotherapy, all patients were treated with intravenous palonosetron 0.25 mg and dexamethasone 12 mg, and oral aprepitant 125 mg. On day 2–4, patients randomly received oral dexamethasone 8 mg plus aprepitant 80 mg once daily (days 2–3) or metoclopramide 20 mg four times daily plus dexamethasone 8 mg bid. Primary endpoint was rate of complete response (no vomiting, no rescue treatment) in day 2–5 after chemotherapy. Due to difficulty in the accrual of patients, 303 of the 480 planned patients were enrolled, 284 were fully evaluable, 147 receiving A + D, 137 M + D. Day 1 results were similar in both arms. On day 2–5, complete response rate was not significantly different (80.3% with A + D versus 82.5% with M + D, P < 0.38, respectively), and all secondary endpoints were also similar (complete protection, total control, no vomiting, no nausea, and score of Functional Living Index-Emesis; P < 0.24). Adverse events incidence was not significantly different between the two treatments. In cancer patients submitted to cisplatin-based chemotherapy, receiving the same antiemetic prophylaxis for acute emesis, A + D is not superior to M + D in preventing delayed emesis, and both treatments present similar toxicity. NCT00869310.
- 5 March 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26 (6) , 1248-1253
Open AccessAprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study
A combination of aprepitant, a 5-HT3 receptor antagonist (r.a.), and dexamethasone is recommended for the prophylaxis of cisplatin-induced nausea and vomiting in the acute phase, and aprepitant + dexamethasone (A + D) in the delayed phase. The aim of this study was to verify if A + D is superior to metoclopramide plus dexamethasone (M + D) in preventing delayed emesis in cancer patients receiving the same prophylaxis for acute emesis. A randomized double-blind study comparing A + D versus M + D was completed in previously untreated cancer patients. Before chemotherapy, all patients were treated with intravenous palonosetron 0.25 mg and dexamethasone 12 mg, and oral aprepitant 125 mg. On day 2–4, patients randomly received oral dexamethasone 8 mg plus aprepitant 80 mg once daily (days 2–3) or metoclopramide 20 mg four times daily plus dexamethasone 8 mg bid. Primary endpoint was rate of complete response (no vomiting, no rescue treatment) in day 2–5 after chemotherapy. Due to difficulty in the accrual of patients, 303 of the 480 planned patients were enrolled, 284 were fully evaluable, 147 receiving A + D, 137 M + D. Day 1 results were similar in both arms. On day 2–5, complete response rate was not significantly different (80.3% with A + D versus 82.5% with M + D, P < 0.38, respectively), and all secondary endpoints were also similar (complete protection, total control, no vomiting, no nausea, and score of Functional Living Index-Emesis; P < 0.24). Adverse events incidence was not significantly different between the two treatments. In cancer patients submitted to cisplatin-based chemotherapy, receiving the same antiemetic prophylaxis for acute emesis, A + D is not superior to M + D in preventing delayed emesis, and both treatments present similar toxicity. NCT00869310.
- 10 July 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (20) , 2187-2188
Reply to T.L. Ng et al and L. Celio et al
- 10 July 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (20) , 2187-2188
Reply to T.L. Ng et al and L. Celio et al